Friday 6 November 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.

Revenue: −10.1%
EPS: −36.8%
Free cash flow: −70.5%
Total debt: +14.1%

Quarter to September 2026, against a year earlier

14.53 0.24 −1.62%

Follow RDY

Alert me

Market cap: $12.1B
P/E: 44.4×
Fwd P/E: 30.7×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 5.26
Beneish M: −2.59
Dividend safety: 74/100

Overview

Dr. Reddy's Laboratories Ltd (RDY) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a price to free cash flow of 126×. Over the past ten years it has ranged from 0.0× (September 2017) to 563× (October 2024); the current reading is higher than 95% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RDY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Dr. Reddy&#39;s Laboratories Ltd price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RDY/metrics/price-to-free-cash-flow">Dr. Reddy&#39;s Laboratories Ltd (RDY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2026	53.6×	(23.37%)
FY2025	70.0×	30.80%
FY2024	53.5×	175.54%
FY2023	19.4×	(65.78%)
FY2022	56.7×	76.62%
FY2021	32.1×	53.69%
FY2020	20.9×	0.66%
FY2019	20.8×	(57.88%)
FY2018	49.3×	—
FY2017	0.0×	—

Period	Price to free cash flow	Change
Sep 2026	109×	34.03%
Jun 2026	81.7×	52.28%
Mar 2026	53.6×	32.11%
Dec 2025	40.6×	(23.28%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 563×

Ten-year median 34.4×

Current reading's percentile 95

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
VTRS Viatris Inc. compare	10.7×
NBIX Neurocrine Biosciences, Inc. compare	15.7×
LNTH Lantheus Holdings, Inc. compare	16.9×
ALKS Alkermes plc compare	32.8×
ELAN Elanco Animal Health Incorporated compare	33.2×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc. compare	67.3×
RDY Dr. Reddy's Laboratories Ltd	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Dr. Reddy's Laboratories Ltd (RDY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RDY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on RDY

Stockrow Weekly